Patients with malignancy visiting our outpatient clinic who have a pain intensity of at least 5 on a visual analogue scale (ranging from 0-10) can be included.
Conditions
Interventions
Heart rate variability measurements will be performed on day 0 (before start of pain medication), day 2 and day 7.
Sponsors
UMCG
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients with known metastatic malignancy; 2. Patients with a pain intensity of at least 5 on a visual analogue pain scale; 3. Patients able to have heart rate measures taken; 4. Patients able to fill in the EORTC QLQ-C30; 5. Patients should have sinus rhythm; 6. Performance score 0, 1 or 2; 7. Informed consent should be given.
Exclusion criteria
Exclusion criteria: 1. Patients with neuropathic pain; 2. Patients using medication that interferes with HRV; 3. Patients who have hemodynamically significant cardiac valvular abnormalities, severe chronic heart failure (NYHA III-IV), a history of vagotomy or sympathectomy; 4. Patients with other conditions / illnesses that can influence autonomic function; 5. Patients with brain metastases; 6. Patients who are treated with chemotherapy; 7. Patients who will start with chemotherapy and/or radiotherapy within the week of the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Correlation between the pain intensity as measured by the visual analogue scale and as measured by heart rate variability. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Correlation between the response to pain medication using the visual analogue scale and the EORTC QLQ-C30 questionnairel; 2. correlation between the response to pain medication using heart rate variability measures and the EORTC QLQ-C30 questionnaire. | — |
Contacts
Public ContactA. Reyners
Outcome results
None listed